Paracetamol Infusion Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Paracetamol Infusion Market By Application (Fever, Pain, Patent Ductus Arteriosus, and Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Paracetamol Infusion Market was valued at USD 699.1 million in 2021 and is expanded to grow at a significant CAGR of 3.86% over 2022-2028. The increased application of paracetamol as a first-line pain and fever reliever propels the global paracetamol infusion market forward.  The National Health Service (NHS), The National Institute for Health and Care Excellence (NICE), and the Centers for Disease Control and Prevention (CDC) have all advised paracetamol because of its broad availability. Initially, the COVID-19 pandemic created a rise in market for over-the-counter medicines like paracetamol, causing local authorities to place export limits on key drugs while maintaining acceptable supply levels in their country. Likewise, the drug’s broad use in COVID-19-affected patients to control various symptoms of cold, cough, and fever is projected to boost market expansion. Furthermore, supportive government policies and schemes such as Pharma Vision 2020, the construction of bulk drug parks, and the production linked incentive programme for domestic bulk drug production are likely to generate attractive chances for market growth in the coming years. People suffering from high fevers and aches and pains linked with the flu frequently take paracetamol. Influenza is a problem in tropical areas. The market is growing due to the rising burden of symptomatic conditions and the usage of OTC medications. Following COVID-19, the Indian chemists’ association has agreed not to dispense cold, cough, and fever drugs to anyone without a prescription. However, following the epidemic, local market players expanded paracetamol manufacturing and attempts to encourage availability. Amid the pandemic, increased paracetamol production by local market players, as well as steps to stimulate availability, is projected to drive segment growth throughout the forecast period. The application fever and pain segment is expected to hold the most significant market share in the forecasting years. The rising prevalence of pain and fever is expected the drive this segment. Moreover, COVID-19 has led to a positive impact on the global paracetamol infusion market.

 

Recent Market Developments:

In June 2021, Ethypharm has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use.

 

In May 2022, Sun Pharmaceutical Industries Limited announced that one of its subsidiaries, S.C. Terapia S.A., Romania has acquired the UractivTM portfolio from Fiterman Pharma in Romania.

Paracetamol Infusion Market

MARKET SUMMARY
-
3.86%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 3.86%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Paracetamol Infusion Market

  • The report on global paracetamol infusion market gives historical, current, and future market sizes (US$ Mn) on the basis of application and region
  • paracetamol infusion market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Altan Pharma Limited
  • Unital Pharmaceuticals
  • Stellar- Bio Labs
  • Sun Pharma
  • Amgen, Inc
Paracetamol Infusion Market Dynamics

The rising prevalence of conditions like headaches, flu etc. and the increasing demand for pain management drugs are the major growth drivers for the paracetamol infusion market. Paracetamol is widely used in treatment of mild to moderate pains, including headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches, and pains. Furthermore, it is an effective antipyretic used to reduce fever. However, the side effects associated with the use of paracetamol may hamper the market. Common side effects of paracetamol includes rash, itching, difficulty breathing or swelling of face, lips, throat or tongue.


North-America Got Significant Share

Paracetamol Infusion Market

Throughout the projected period, North America is anticipated to dominate the global paracetamol infusion market. The presence of important players, the high prevalence of fever, headaches, and migraine in the region, and the developed healthcare infrastructure are some of the key factors responsible for the market's huge share. According to data, the growing patient pool and rising disposable income in this country are also predicted to boost the region's market growth. Asia Pacific paracetamol infusion market is growing at a significant rate due to increasing geriatric population, lower cost of drug, quick relief from pain and fever.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Paracetamol Infusion Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The paracetamol infusion market is projected to expand at a CAGR of 3.86% during the forecast period

Altan Pharma Ltd., Abbott, Inc., Cipla Ltd., B. Braun Melsungen AG, Pfizer, Inc., Intas Pharmaceuticals Ltd., Taro Pharmaceutical Industries Ltd., Ipca Laboratories Ltd., Sun Pharmaceutical Industries, Ltd., Biocon Limited

North American is the fastest-growing region for paracetamol infusion market


Report

Table Of Content

1. Executive Summary
2. Global Paracetamol Infusion Market Introduction
2.1. Global Paracetamol Infusion Market – Taxonomy
2.2. Global Paracetamol Infusion Market –Definitions
2.2.1. Distribution Channel
2.2.2. Region
3. Global Paracetamol Infusion Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Current Trends
3.5. Global Paracetamol Infusion Market Dynamic Factors – Impact Analysis
3.6. Mergers, Acquisitions, and Collaborations
4. Global Paracetamol Infusion Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Paracetamol Infusion Market, By Distribution Channel Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
5.1. Hospital Pharmacies
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Retail Pharmacies
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Online Pharmacies
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Paracetamol Infusion Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
6.1. North America
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Europe
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Asia Pacific
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Latin America
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Middle East and Africa
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Global Paracetamol Infusion Market – Opportunity Analysis Index, By Distribution Channel, and Region, 2022 – 2028
7. North America Paracetamol Infusion Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
7.1. Distribution Channel Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
7.1.1. Hospital Pharmacies
7.1.2. Retail Pharmacies
7.1.3. Online Pharmacies
7.2. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
7.2.1. United States
7.2.2. Canada
7.3. North America Paracetamol Infusion Market – Opportunity Analysis Index, By Distribution Channel, and Country, 2017-2028
7.4. North America Paracetamol Infusion Market Dynamics – Trends
8. Europe Paracetamol Infusion Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
8.1. Distribution Channel Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Hospital Pharmacies
8.1.2. Retail Pharmacies
8.1.3. Online Pharmacies
8.2. Country Level Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
8.2.1. UK
8.2.2. Germany
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Europe Paracetamol Infusion Market – Opportunity Analysis Index, By Distribution Channel, and Country, 2017-2028
8.4. Europe Paracetamol Infusion Market Dynamics – Trends
9. Asia Pacific Paracetamol Infusion Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
9.1. Distribution Channel Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Hospital Pharmacies
9.1.2. Retail Pharmacies
9.1.3. Online Pharmacies
9.2. Country Level Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
9.2.1. China
9.2.2. India
9.2.3. ANZ
9.2.4. Japan
9.2.5. Rest of APAC
9.3. Asia Pacific Paracetamol Infusion Market – Opportunity Analysis Index, By Distribution Channel, and Country, 2017-2028
9.4. Asia Pacific Paracetamol Infusion Market Dynamics – Trends
10. Latin America Paracetamol Infusion Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
10.1. Distribution Channel Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Hospital Pharmacies
10.1.2. Retail Pharmacies
10.1.3. Online Pharmacies
10.2. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Argentina
10.2.4. Rest of LA
10.3. Latin America Paracetamol Infusion Market – Opportunity Analysis Index, By Distribution Channel, and Country, 2016-2027
10.4. Latin America Paracetamol Infusion Market Dynamics – Trends
11. MEA Paracetamol Infusion Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Mn) and Volume (‘000 Units))
11.1. Distribution Channel Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue (USD Mn) and Volume (‘000 Units)), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Hospital Pharmacies
11.1.2. Retail Pharmacies
11.1.3. Online Pharmacies
11.2. MEA Paracetamol Infusion Market – Opportunity Analysis Index, By Distribution Channel, and Country, 2017-2028
11.3. MEA Paracetamol Infusion Market Dynamics – Trends
12. Competition Landscape 
12.1. Strategic Dashboard of Top Market Players
12.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
12.2.1. Altan Pharma Ltd.
12.2.2. Abbott, Inc.
12.2.3. Cipla Ltd.
12.2.4. B. Braun Melsungen AG
12.2.5. Pfizer, Inc.
12.2.6. Intas Pharmaceuticals Ltd.
12.2.7. Taro Pharmaceutical Industries Ltd.
12.2.8. Ipca Laboratories Ltd.
12.2.9. Sun Pharmaceutical Industries, Ltd.
12.2.10. Biocon Limited
13. Research Methodology
14.Key Assumptions and Acronyms

Report

Company Profile

  • Altan Pharma Limited
  • Unital Pharmaceuticals
  • Stellar- Bio Labs
  • Sun Pharma
  • Novartis
  • Cipla
  • Pfizer
  • Amgen, Inc

Description

Paracetamol Infusion Market was valued at USD 699.1 million in 2021 and is expanded to grow at a significant CAGR of 3.86% over 2022-2028. The increased application of paracetamol as a first-line pain and fever reliever propels the global paracetamol infusion market forward.  The National Health Service (NHS), The National Institute for Health and Care Excellence (NICE), and the Centers for Disease Control and Prevention (CDC) have all advised paracetamol because of its broad availability. Initially, the COVID-19 pandemic created a rise in market for over-the-counter medicines like paracetamol, causing local authorities to place export limits on key drugs while maintaining acceptable supply levels in their country. Likewise, the drug’s broad use in COVID-19-affected patients to control various symptoms of cold, cough, and fever is projected to boost market expansion. Furthermore, supportive government policies and schemes such as Pharma Vision 2020, the construction of bulk drug parks, and the production linked incentive programme for domestic bulk drug production are likely to generate attractive chances for market growth in the coming years. People suffering from high fevers and aches and pains linked with the flu frequently take paracetamol. Influenza is a problem in tropical areas. The market is growing due to the rising burden of symptomatic conditions and the usage of OTC medications. Following COVID-19, the Indian chemists’ association has agreed not to dispense cold, cough, and fever drugs to anyone without a prescription. However, following the epidemic, local market players expanded paracetamol manufacturing and attempts to encourage availability. Amid the pandemic, increased paracetamol production by local market players, as well as steps to stimulate availability, is projected to drive segment growth throughout the forecast period. The application fever and pain segment is expected to hold the most significant market share in the forecasting years. The rising prevalence of pain and fever is expected the drive this segment. Moreover, COVID-19 has led to a positive impact on the global paracetamol infusion market.

 

Recent Market Developments:

In June 2021, Ethypharm has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use.

 

In May 2022, Sun Pharmaceutical Industries Limited announced that one of its subsidiaries, S.C. Terapia S.A., Romania has acquired the UractivTM portfolio from Fiterman Pharma in Romania.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX